Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E28.85 EPS (ttm)1.17 Insider Own0.04% Shs Outstand6.07B Perf Week-0.71%
Market Cap204.23B Forward P/E12.14 EPS next Y2.77 Insider Trans-7.90% Shs Float5.95B Perf Month-2.41%
Income7.20B PEG4.83 EPS next Q0.67 Inst Own73.20% Short Float1.11% Perf Quarter6.96%
Sales52.83B P/S3.87 EPS this Y5.20% Inst Trans-0.02% Short Ratio2.82 Perf Half Y5.28%
Book/sh9.80 P/B3.43 EPS next Y8.67% ROA4.20% Target Price37.80 Perf Year5.04%
Cash/sh2.94 P/C11.44 EPS next 5Y5.97% ROE11.60% 52W Range29.24 - 36.35 Perf YTD4.63%
Dividend1.28 P/FCF31.01 EPS past 5Y3.30% ROI7.80% 52W High-7.44% Beta0.97
Dividend %3.80% Quick Ratio1.00 Sales past 5Y-2.80% Gross Margin76.70% 52W Low15.06% ATR0.32
Employees96500 Current Ratio1.30 Sales Q/Q-3.00% Oper. Margin17.00% RSI (14)39.92 Volatility0.87% 0.91%
OptionableYes Debt/Eq0.71 EPS Q/Q600.90% Profit Margin13.70% Rel Volume1.00 Prev Close33.74
ShortableYes LT Debt/Eq0.53 EarningsMay 02 BMO Payout101.50% Avg Volume23.48M Price33.64
Recom2.50 SMA20-1.27% SMA50-0.89% SMA2001.49% Volume23,382,904 Change-0.30%
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-23-17 06:42AM  If You're in Your 50s, Consider Buying These 3 Stocks Motley Fool
Apr-22-17 01:00PM  Trump Executive Order Could Revive Allergan-Pfizer Merger
09:48AM  Better Buy: AbbVie Inc. vs. Pfizer Motley Fool
12:08AM  FDA OKs Samsung Bioepiss Biosimilar Version Of J&Js Remicade The Wall Street Journal
Apr-21-17 05:03PM  FDA OKs Samsung Bioepis's Biosimilar Version Of J&J's Remicade The Wall Street Journal
03:05PM  Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia Business Wire
12:00PM  Making Drug Manufacturing Great Again Investor's Business Daily
08:36AM  Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries Business Wire
Apr-20-17 03:00PM  Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders Business Wire
10:47AM  Bristol-Myers Squibb Co: Buy the Dip? Motley Fool
09:55AM  3 Top High-Yield Dividend Stocks to Buy Now Motley Fool
Apr-19-17 09:13PM  Pfizer subpoenaed in U.S. intravenous saline solution probe Reuters
05:02PM  Pfizer Follows Baxter, Gets Slammed With Subpoena Related To Saline Shortage Investor's Business Daily
04:17PM  Is J&J's Pharma Sales Slowdown a Warning for Other Players? Zacks
04:03PM  Pfizer is latest to get Justice Department subpoena in intravenous saline investigation MarketWatch
03:13PM  Pfizer Inc. Value Analysis (NYSE:PFE) : April 19, 2017 Capital Cube
03:05PM  Pfizer subpoenaed in U.S. intravenous saline solution probe Reuters
11:42AM  Gilead Sciences: Who's Frustrated Now?
11:05AM  Billionaires, companies power Trump's record inaugural haul Associated Press
10:57AM  Pfizer receives subpoenas in U.S. intravenous saline solution probe Reuters
07:05AM  Why Is Pfizer (PFE) Up 8.7% Since the Last Earnings Report? Zacks
Apr-18-17 02:11PM  Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition
11:41AM  High-Yield Healthcare Investments You Can Buy Right Now Motley Fool
11:19AM  Johnson & Johnson says pricing competition squeezed 1Q sales Associated Press
11:04AM  The 4 Best Dividend Stocks in Pharmaceuticals Motley Fool
08:33AM  Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : April 18, 2017 Capital Cube
Apr-17-17 11:56PM  [$$] Papua New Guinea struggles to eradicate yaws disease Financial Times
08:43PM  The makers of a lethal-injection drug have become leaders in Arkansas' death-penalty battle Business Insider
08:30PM  5 Stocks To Profit From The Canadian Marijuana Boom
06:13PM  5 Things You Should Expect When Johnson & Johnson Reports Its Q1 Results Tomorrow Motley Fool
05:43PM  Billion dollar drug bust CNBC Videos
04:22PM  How Pfizer Inc. Makes Most of Its Money Motley Fool
04:13PM  Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug? Investor's Business Daily
12:47PM  Why Incyte Corporation Stock Is Plunging Today Motley Fool
10:51AM  Gilead, Pfizer, AbbVie Win From Lilly's Loss
09:46AM  Stocks Open Higher: McDonald's, Apple Rise On The Dow Investor's Business Daily
09:20AM  5 Drug Stocks That Could Be Big Winners this Earnings Season Zacks
03:30AM  Overcoming Opioids: The quest for less addictive drugs Associated Press
Apr-16-17 09:33PM  Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis
Apr-13-17 09:38PM  2 firms seek to prevent drugs' use in Arkansas executions Associated Press
08:27PM  2 firms seek to prevent drugs' use in Arkansas executions Associated Press
06:17PM  Pfizer Says Execution Drugs Sold to Arkansas Without Knowing Bloomberg
11:00AM  A Direct Approach to Value Stocks Investopedia
10:22AM  J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat? Zacks
Apr-12-17 11:46AM  Healthcare Sector Earnings: Making A Comeback In Q1 2017? Benzinga
Apr-11-17 04:29PM  What's Got Axovant Sciences Jumping 10% Today? Motley Fool
11:45AM  Boston biotech Rhythm elevates Genzyme head Meeker to board chairman American City Business Journals
11:09AM  Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma
08:08AM  The 3 Top Dividend Stocks in the Healthcare Sector Motley Fool
Apr-10-17 11:37AM  Roche Cancer Drug Beats Pfizer's Xalkori in Study Investopedia
10:11AM  3 Top Dividend Stocks to Put on Your Shopping List Motley Fool
08:50AM  3 Dividend Stocks That Should Pay for the Rest of Your Life Motley Fool
08:15AM  Medivation Founder David Hung Becomes CEO Of Axovant Sciences Forbes
07:36AM  How Pfizer Stock Performed in 1Q17 Market Realist
01:38AM  Roche's Alecensa notches trial win against Pfizer's Xalkori Reuters
Apr-07-17 12:25PM  FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements Benzinga
11:57AM  How Pharmaceutical ETFs Performed during 1Q17 Market Realist
Apr-06-17 10:48AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
Apr-05-17 05:00PM  DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control
04:44PM  The 3 Most Important Numbers for Pfizer Inc. Motley Fool
03:36PM  Advertisers flee Bill O'Reilly's show but impact unclear Associated Press
09:06AM  What Wall Street Analysts Recommend for Pfizer Market Realist
07:36AM  Must-Know Corporate and Pipeline Developments for Pfizer Market Realist
Apr-04-17 12:25PM  Onconova Reports Positive Data for 2 Cancer Drugs Investopedia
12:24PM  There's Value in Healthcare ETFs Investopedia
10:36AM  These Key Product Developments Could Help Pfizer Market Realist
09:15AM  Today's Research Reports on Stocks to Watch: Mylan and Pfizer Accesswire
09:08AM  Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs MarketWatch
09:06AM  Whats Pfizers Financial Guidance for 2017?
08:03AM  Amgen Offers A Money-Back Guarantee For Its Cholesterol Drug Repatha
07:37AM  These Pfizer Products Saw Declining Revenues in 2016
Apr-03-17 01:38PM  Mylan's EpiPen Recall Expanded to U.S.
11:49AM  The 8 'Dogs Of The Dow' Of 2017 Lag On Weakness From Chevron And These 2 Stocks
10:41AM  What Contributed to Pfizers Growth in 2016?
10:10AM  Mylan Expands EpiPen Recall
09:39AM  Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance
09:08AM  Analyzing Pfizers Geographical Performance in 2016
08:49AM  Pfizer's Ibrance Gets FDA Approval for Breast Cancer at Investopedia
07:38AM  How Pfizers Innovative and Essential Health Segments Performed
02:00AM  The cost of cancer: new drugs show success at a steep price Reuters
Mar-31-17 10:54PM  White House wealth: Trump employees disclose their finances
05:55PM  How Does Pfizers Valuation Compare to Peers?
03:32PM  3 Attractive Healthy Dividend-Paying Market Gems at Forbes
03:29PM  Understanding Sanofis Valuation Compared to Peers
02:04PM  IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer Business Wire
12:48PM  Merck, Incyte Expand Cancer Collaboration at
12:19PM  Novartis Focuses on Portfolio Prioritization to Boost Profitability
10:35AM  Entresto Could See Strong Uptake in European Markets in 2017
08:21AM  Could Pfizer Buy Esperion Therapeutics? at Motley Fool
Mar-30-17 04:30PM  These 5 Dow Stocks Are Near Buy Points: Investing Action Plan
10:36AM  Reduced Co-pays May Boost Demand for Entresto
09:16AM  Viagra May Be Soon Be Sold Without a Prescription in the UK at Investopedia
07:36AM  Why Entresto Could Become Key Growth Driver for Novartis in 2017
Mar-29-17 04:50PM  Eli Lillys Valuation Compared to Its Peers
04:01PM  VBI Vaccines Emerges as Strong Biotech Stock
03:42PM  3 Drugmakers With Boatloads of Cash to Spend at Motley Fool
11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA at Investopedia
07:36AM  What Wall Street Analysts Recommend for Merck
Mar-28-17 06:51PM  Cramer's lightning round: Stick with this 'terrific' defense play at CNBC
06:05PM  Will Novartis See Rise in Net Profit Margins in 2017?
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON RADY AExecutive Vice PresidentMar 10Sale34.194,500153,85554,963Mar 13 05:36 PM
HILL CHARLES HExecutive Vice PresidentMar 09Sale34.0736,0001,226,52057,329Mar 10 03:59 PM
Dolsten MikaelPresident R&DMar 02Sale34.5515,401532,10549,318Mar 03 04:06 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 02Sale34.6620,000693,20083,793Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 01Sale34.4815,569536,81964,719Mar 03 04:06 PM
Dolsten MikaelPresident R&DFeb 27Sale34.2658,8462,016,24480,288Mar 01 05:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63572,172Feb 27 06:30 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.03103,1552,169,350295,356Feb 27 06:30 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0351,5781,084,685138,758Feb 27 06:30 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63533,848Feb 27 06:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03218,4474,593,940592,765Feb 27 06:21 PM
BOURLA ALBERTGroup PresidentFeb 23Option Exercise21.0342,476893,270165,474Feb 27 06:21 PM
Dolsten MikaelPresident R&DFeb 23Option Exercise21.03218,4474,593,940299,915Feb 27 06:21 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0336,408765,660102,611Feb 27 06:10 PM
READ IAN CChairman & CEOFeb 23Option Exercise21.03788,83516,589,2001,124,093Feb 27 06:55 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.03115,2912,424,570247,765Feb 27 06:55 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0351,5781,084,685172,542Feb 27 06:56 PM
OLSON LAURIE JExecutive Vice PresidentFeb 23Option Exercise21.0327,306574,24599,224Feb 27 06:47 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM